Inhibition of Expression in *Escherichia coli* of a Virulence Regulator MglB of *Francisella tularensis* Using External Guide Sequence Technology

Gaoping Xiao¹, Eirik W. Lundblad¹,², Mina Izadjoo³, Sidney Altman¹*

¹ Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut, United States of America, ² Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromso, Norway, ³ Armed Forces Institute of Pathology, Washington, D. C., United States of America

Abstract

External guide sequences (EGSs) have successfully been used to inhibit expression of target genes at the post-transcriptional level in both prokaryotes and eukaryotes. We previously reported that EGS accessible and cleavable sites in the target RNAs can rapidly be identified by screening random EGS (rEGS) libraries. Here the method of screening rEGS libraries and a partial RNase T1 digestion assay were used to identify sites accessible to EGSs in the mRNA of a global virulence regulator MglB from *Francisella tularensis*, a Gram-negative pathogenic bacterium. Specific EGSs were subsequently designed and their activities in terms of the cleavage of mglB mRNA by RNase P were tested in vitro and in vivo. EGS73, EGS148, and EGS155 in both stem and M1 EGS constructs induced mglB mRNA cleavage in vitro. Expression of stem EGS73 and EGS155 in *Escherichia coli* resulted in significant reduction of the mglB mRNA level coded for the *F. tularensis* mglB gene inserted in those cells.

Introduction

*Francisella tularensis* is a Gram-negative, facultative intracellular bacterium that is the etiological agent of tularemia [1]. Tularemia is primarily a disease of the Northern hemisphere that is spread by blood-sucking insects or acquired from contact with infected animals such as rabbits or rodents. In addition, *F. tularensis* is a category A agent of biowarfare/biodefense due to its high infectivity and lethality when inhaled [2]. Survival and replication inside macrophages of hosts is important for the virulence of *F. tularensis*. The MglA and MglB proteins encoded in an operon regulate transcription of a particular set of genes, some of which are required for intramacrophage growth and virulence of *F. tularensis* [2–6].

Inhibition of gene expression at the RNA level has been achieved by base-pairing EGSs with mRNAs of specific genes to form a complex mimicking the natural substrates of RNase P [7–11]. RNase P is a ubiquitous enzyme and its prime physiological role is to cleave tRNA precursors (ptRNAs) to generate the 5′ termini of mature tRNA molecules [12]. RNase P can specifically cleave any RNA in vitro and in vivo, provided that the target RNA is hybridized to an EGS that is complementary to the targeted region [13,14]. EGSs have been designed to convert antimicrobial resistance to sensitivity [8,11], inhibit bacterial viability, and decrease secretion of virulence factors involved in host cell invasion in Gram-negative bacteria [9,10].

In *Escherichia coli*, RNase P consists of M1 RNA and C5 protein. The M1 RNA can execute the enzymatic function in vitro in the absence of the C5 protein. Depending on whether or not M1 RNA is covalently linked with an EGS, EGSs are classified as M1 EGSs and stem EGSs, respectively.

Here we describe application of stem and M1 EGSs to induce *F. tularensis* mglB mRNA cleavage by RNase P in *E. coli*. Stem and M1 EGSs targeting positions 73, 148, and 155 cleaved the mglB mRNA in vitro. Expression of stem EGSs targeting positions 73 and 155 resulted in a 50–60% reduction of the mglB mRNA level in *E. coli*.

A similar successful method has been described to test EGSs on different pathogens [15].

Results

Mapping in vitro of accessible sites in the mglB mRNA

Many RNAs spontaneously self-assemble into highly folded structures. EGS accessible sites within target RNAs are determined to facilitate the design of specific EGSs. Several methods have been successfully used to identify accessible sites on various target RNAs [16,17]. In this study, the rapid rEGS assay was used to screen for stem EGSs that selectively cleave the target mglB mRNA. An effective stem EGS candidate should meet the following requirements: an EGS-directed cleavage reaction occurs only if the target RNA is incubated with both rEGS and the RNase P holoenzyme; the amount of cleavage product increases as the amount of rEGS increases. Figure 1A suggests that an EGS targets the position 155 (Fig. 1A and 1B).
The 5' end nucleotide of ptRNA cleavage products of RNase P is guanine (G) in most cases. The rEGSs consisting of the random 14-nucleotide sequence (N14) and a cytosine (C) were designed to bind to a G nucleotide in the target RNA. Interestingly, the nucleotide at position 155 in the mglB RNA is a C rather than a G. In principle, the nucleotide next to the CACCA sequence in rEGS(s) might be G, which base-pairs with the nucleotide C at the position 155 of the mglB sequence.

As described previously for screening rEGSs targeting the vjbR mRNA of Brucella melitensis [17], both rEGSe and rEGSx libraries were used (Fig. 1A). The only difference between rEGSe and rEGSx is the shorter length of the 3' end of rEGSx mRNA that resulted from the BstNI digestion of the DNA fragments for in vitro transcription. Consistent with previous report (17), the rEGSx library gave much stronger cleavage than the rEGSe library (Fig. 1A).

The partial RNase T1 digestion assay is normally used to locate the exposed G nucleotides in the target RNA [18]. The signal strength of bands in the T1 lane in Figure 1A indicates the accessibility of the G nucleotides in the mglB mRNA (Fig. 1A and 1B). Although not identified by the rEGS assay, positions 52, 73, and 148 could be EGS accessible sites (Fig. 1A and 1B).

Cleavage in vitro of the mglB mRNA by specific EGSs

Stem EGSs and M1 EGSs targeting the potential cleavage sites, 52, 73, 148, and 155 (rEGS52, EGS73, EGS148, and EGS155), were respectively demonstrated and tested in cleavage assays in vitro. To follow the sequence of rEGSs, N14CACCA, we designed EGS155R assuming the targeted position 155 to be a G nucleotide. EGS155, which perfectly base-pairs with the target mglB sequence, was also designed. Figures 2A and 2B indicate that stem EGSs targeting positions 73, 148, and 155 were able to cleave the mglB mRNA. Increase of the EGSs concentration resulted in increase of the amount of cleavage products (Fig. 2A and 2B). Failure in base-pairing of the nucleotide immediately next to ACCA in EGS155R with the target mglB sequence resulted in loss of cleavage activity (Fig. 2B). The cleavage sites were confirmed as shown in Figure 1A by 5' end-labeling the mglB mRNA, cleavage assays in vitro, and then separation by denaturing PAGE with alkali-treated mglB mRNA and partial RNase T1 digested mglB mRNA as size markers (data not shown).

Figures 3A and 3B show that higher concentration of Mg2+ (100 mM) induced the M1 EGSs in the absence of RNase P holoenzyme to give the same cleavage patterns as the correspond-
ing stem EGSs in the presence of E. coli RNase P holoenzyme (Fig. 2A, 2B, 3A, and 3B). Consistent with the results of stem EGSs, only M1 EGSs targeting positions 73, 148, and 155 cleaved the mglB mRNA. Increase of the M1 EGSs concentration resulted in increase of the amount of cleavage products (Fig. 3A and 3B). M1 EGS52 and M1 EGS155R could not cleave the mglB mRNA (Fig. 3B and data not shown).

Specific EGSs induce reduction of the mglB mRNA level in E. coli
To confirm if EGS73, EGS148, and EGS155 induce reduction of the mglB mRNA level in vivo, we transcribed the mglB gene from the same plasmid in E. coli by creating the plasmids pMlac-mglB-EGS73, pMlac-mglB-M1EGS73, pMlac-mglB-M1EGS148, and pMlac-mglB-M1EGS155.

Transcription of mglB was under the control of the nptB promoter and transcription of EGSs under the control of the IPTG-inducible T7 promoter (data not shown). To avoid the mutual influence of the two promoters, mglB and EGSs were transcribed in opposite directions. Figures 4A and 4B show that IPTG-induced expression of stem EGS73 and EGS155 resulted in reduction of the mglB mRNA level to 40–50% of that without the EGSs in E. coli cells. Surprisingly, the mglB mRNA level increased in the presence of leaky expression of stem EGS148 for unknown reasons but increase of EGS148 transcription still resulted in reduction of the mglB mRNA level (Fig. 4A and 4B). None of the
The method of screening rEGS libraries has successfully been used to identify accessible and cleavable sites in the target RNA [17]. All specific EGSs that we have designed so far based on the results of the rEGS method are able to cleave the target mRNAs [17]. The efficiency of the rEGS method is better than that of any other method that has been used, including the partial RNase T1 digestion assay. However, in some cases where we searched for rEGS, we have been unable to identify any EGS-induced cleavable site or EGS accessible sites that were identified by other methods [15,17]. There are two ways to solve the problem. One is to combine the results of the rapid rEGS method and the partial RNase T1 digestion assay to design specific EGSs, as we did in this study. The other is to make a transcript of the target gene that is much larger than the one used in this case so that the whole landscape of the targeted gene is examined.

The nucleotide G is preferred to lie immediately next to the natural ptRNA cleavage site and base-pairs with the nucleotide C in the 3’ end of the ptRNA cleavage product [17]. When we originally designed the rEGS libraries, we used the nucleotide C after the N14 sequence and before the ACCA sequence to base-pair with the nucleotide G in target RNAs [17]. Interestingly, the nucleotide C at the position 155 of the mglB sequence identified by the rEGS method does not follow this rule. However, difference in base-pairing of a single nucleotide in EGS155 and EGS155R with the nucleotide G significantly affects EGS-induced RNase P cleavage activity (Fig. 2A), suggesting the importance of base-pairing between EGSs and the nucleotide next to the cleavage site. The interaction between the nucleotide T at the position 156 of the mglB sequence and the nucleotide A next to the ACCCA sequence in EGS155R may be too weak to form a mRNA-EGS complex to induce RNase P cleavage activity.

While we have outlined a safe method to test the effect of EGSs on genes from pathogenic bacteria in this report, we also note that shuttle plasmids that contain the successful EGSs have been constructed and are now in the process of being tested in the actual pathogens in BL3 facilities of the Armed Forces Institute of Pathology. The efficiency of EGS inactivation of expression of target genes can be enhanced by putting two EGSs attacking different sites on the target mRNA on a shuttle plasmid. Indeed, two EGSs attacking the same site can also be used. Agents that can be injected into mice or administered to them by nasal inhalation will be used in these experiments. Chemically modified EGSs that can be taken up by bacteria (Avi Biopharma, Corvallis, Oregon) should be used in this respect and might be successful. Clinical application of these EGSs will rely on the results of the mouse experiments.

Materials and Methods

Materials

Oligonucleotides were made by the Yale synthesis facility (New Haven, CT). Restriction endonucleases, DNA polymerase I Klonev fragment, T4 polynucleotide kinase, and T4 DNA ligase were purchased from New England Biolabs (Cambridge, MA). SP6 and T7 RNA polymerases were purchased from Promega (Madison, WI). Qiaquick PCR purification kit, Qiaquick gel extraction kit, and Qiaprep spin miniprep kit were purchased from Qiagen (Chatsworth, CA). AmpliTaq DNA polymerase was purchased from Roche (Indianapolis, IN). Ultrafree-MC column was purchased from Millipore (Billerica, MA). [γ-32P]ATP and [γ-32P]GTP were purchased from Amersham (Piscataway, NJ) and PerkinElmer (Boston, MA).

Strains and growth conditions

Bacterial strains used are listed in Table 1. E. coli cells were grown at 37°C in Luria-Bertani (LB) broth or on LB agar. E. coli
Inhibition of mglB Expression

Table 1. Bacterial strains and plasmids.

| Strains/Plasmids | Relevant characteristics | References/Source |
|-------------------|--------------------------|-------------------|
| **Strains**       |                          |                   |
| DH5α              | F- Δ80lacZΔM15 Δ(lacYA-argF)U169 deoR recA1 endA1 hsdR17(rK-,mK-) phoA supE44 λ- thi-1 gyrA96 relA1 | Lab collection |
| BL21(DE3)         | F- ompT hsdS (rK-, mK-) gal dcm λ (DE3) | Novagen |
| **Plasmids**      |                          |                   |
| pGEM-T            | Cloning vector; Amp′     | [22]              |
| pGEMmglB          | pGEM-T with mglB PCR product; Amp′ | This study |
| pGEΔmglB          | pGEMmglB with ApaI-SacI deletion; Amp′ | This study |
| pSupS1            | pSP64 with tRNA™ insert; Amp′ |                   |
| pUC7/7/AEFRNAAHHT7T | pUC19-derived cloning vector with T7 promoter and terminator, and HH sequence; Amp′ | Guerrier-Takada C, unpublished |
| pUC7/7/AEFRNAAHHT7T | pUC7/7/AEFRNAAHHT7T with stem EGS52 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/mglBEGS573 | pUC7/7/AEFRNAAHHT7T with stem EGS73 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/mglBEGS148 | pUC7/7/AEFRNAAHHT7T with stem EGS148 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/mglBEGS155 | pUC7/7/AEFRNAAHHT7T with stem EGS155 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/mglBEGS155R | pUC7/7/AEFRNAAHHT7T with stem EGS155R PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/M1AEFRNAAHHT7T | pUC19-derived cloning vector with T7 promoter and terminator, M1 and HH sequence; Amp′ | Guerrier-Takada C, unpublished |
| pUC7/7/M1AEFRNAAHHT7T | pUC7/7/M1AEFRNAAHHT7T with stem EGS52 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/M1AEFRNAAHHT7T | pUC7/7/M1AEFRNAAHHT7T with stem EGS73 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/M1AEFRNAAHHT7T | pUC7/7/M1AEFRNAAHHT7T with stem EGS148 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/M1AEFRNAAHHT7T | pUC7/7/M1AEFRNAAHHT7T with stem EGS155 PstI-BsrEI insert; Amp′ | This study |
| pUC7/7/M1AEFRNAAHHT7T | pUC7/7/M1AEFRNAAHHT7T with stem EGS155R PstI-BsrEI insert; Amp′ | This study |
| pKB283‘3’HHC5EGS13’HHM1T | pUC19-derived cloning vector pKB283 with 5’HHC5EGS13’HH insert; Amp′ | [18] |
| pKB283-mglB       | pKB283 with mglB BamHI-BsrEI insert; Amp′ |                   |
| pMac               | pUC19 with a mutated lacZ promoter; Amp′ | [15] |
| pMac-mglB         | pKB283-mglB with a mutated lacZ promoter; Amp′ | This study |
| pKB283-Mlac       | pKB283‘3’HHC5EGS13’HHM1T with a mutated lacZ promoter; Amp′ | This study |
| pMac-mglB-EG573   | pMac-mglB with stem EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-EG573   | pMac-mglB with stem EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-EG573   | pMac-mglB with stem EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-M1EG573 | pMac-mglB with M1 EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-M1EG573 | pMac-mglB with M1 EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-M1EG573 | pMac-mglB with M1 EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-M1EG573 | pMac-mglB with M1 EG573 HindIII-EcoRI insert; Amp′ | This study |
| pMac-mglB-M1EG573 | pMac-mglB with M1 EG573 HindIII-EcoRI insert; Amp′ | This study |

DH5α was routinely used for subcloning and plasmid propagation. E. coli B/1 (DE3) was used for protein expression. Ampicillin or carbenicillin (100 μg/ml) was used for plasmid selection and maintenance in E. coli.

Preparation of the target mglB mRNA

Restrictive genomic DNA of F. tularensis was obtained from the Armed Forced Institute of Pathology, Washington, DC. The template for the mglB mRNA of F. tularensis was prepared as described previously [17]. To map accessible sites in the mglB mRNA, the 5′ fragment was amplified by PCR using primers mglB F (5′-ATGGCTATGCTTAGAGCATATG-3′) and mglB R (5′-TCATCATCTTCGCTTCTATT-3′). The PCR fragment was sub-cloned into the pGEM-T vector, generating the plasmid pGEMmglB. To reduce the length of the vector sequence between the T7 promoter in the pGEM-T vector and the inserted DNA fragment, the plasmid pGEMmglB was digested with the restriction enzymes ApaI and SacII, purified from an agarose gel using Ultrafree-MC columns, blunt ended using DNA polymerase I Klenow fragment, and then re-ligated using T4 DNA ligase. The resulting plasmid pGEAmglB was digested with the restriction enzymes FokI and TaqI, ethanol-precipitated and dissolved in distilled water, and used as the template for in vitro transcription using T7 RNA polymerase [17]. For internally labeled transcripts, [α-32P]ATP and T4 polynucleotide kinase.

Mapping of accessible sites in the mglB mRNA

The rEGS assay for the mglB mRNA was performed as described previously [17]. Partial RNase T1 reaction was performed as previously described [8]. After the reaction, the

DH5α was routinely used for subcloning and plasmid propagation. E. coli B/1 (DE3) was used for protein expression. Ampicillin or carbenicillin (100 μg/ml) was used for plasmid selection and maintenance in E. coli.

Preparation of the target mglB mRNA

Restrictive genomic DNA of F. tularensis was obtained from the Armed Forced Institute of Pathology, Washington, DC. The template for the mglB mRNA of F. tularensis was prepared as described previously [17]. To map accessible sites in the mglB mRNA, the 5′ fragment was amplified by PCR using primers mglB F (5′-ATGGCTATGCTTAGAGCATATG-3′) and mglB R (5′-TCATCATCTTCGCTTCTATT-3′). The PCR fragment was sub-cloned into the pGEM-T vector, generating the plasmid pGEMmglB. To reduce the length of the vector sequence between the T7 promoter in the pGEM-T vector and the inserted DNA fragment, the plasmid pGEMmglB was digested with the restriction enzymes ApaI and SacII, purified from an agarose gel using Ultrafree-MC columns, blunt ended using DNA polymerase I Klenow fragment, and then re-ligated using T4 DNA ligase. The resulting plasmid pGEAmglB was digested with the restriction enzymes FokI and TaqI, ethanol-precipitated and dissolved in distilled water, and used as the template for in vitro transcription using T7 RNA polymerase [17]. For internally labeled transcripts, [α-32P]ATP was used during the transcription reaction. For the mapping of cleavage sites, transcripts were labeled at the 5′ end using [γ-32P]ATP and T4 polynucleotide kinase.
mRNA was separated on an 8% polyacrylamide sequencing gel that contained 7 M urea. Partial alkaline ladder digests were carried out as previously described [17]. Cleavage sites were determined by comparing rEGS-mediated and partial RNase T1 cleavage products to partial alkaline ladder results. The yeast suppressor precursor tRNA<sup>Mm</sup> (SupS<sup>1</sup>) was internally labeled with [γ-<sup>32</sup>P]GTP and used as a substrate in control reaction [15,19].

Preparation of stem and M1 EGSs against the mglB mRNA

Specific EGSs were designed based on the rEGS assay and partial RNase T1 assay according to previous reports [17,18]. The specific EGSs used for in vitro cleavage assays were phosphorylated at their 5′ ends, annealed together by heating at 95°C for 5 min and cooled down slowly. The annealed oligos had the restriction enzymes PstI and BstEII overhangs at the 5′ and 3′ ends, respectively. These oligos used for EGS52, EGS73, EGS148, EGS155, and EGS155R were 52 (5′-GTGTAATCCATGATACCAAGC-3′), 52 compl (5′-CTGGACCTGGTGTATCTGATGTAATTACCTGCA-3′), 73 (5′-GAGATCATCAAACTACCCAG-3′), 73 compl (5′-GTCAGCCTGTTTCTGTAATCTGTCAGAACA-3′), 148 (5′-GGTGAGGAGAATAATCCAGCAG-3′), 148 compl (5′-GGTGACGCTGCTGTTATTTTGATACCTGCA-3′), 155 (5′-GAGGATTTGCTTGGGAGACCGAC-3′), 155 compl (5′-GGTGACCTGGTCTCTGTAAATACCTGCA-3′), 155R (5′-GTTATAGGTCTTGAGACACCGC-3′), 155R compl (5′-GTGACCTGGTTGCTCCTAATCTACCTGCA-3′). The hybridized EGS oligos were inserted into a pUC19-based vector containing the T7 promoter, pUC7/AEFRNAHHITT7, pre-digested with PstI and BstEII, generating the plasmids pUC7mglBEGS52, pUC7mglBEGS73, pUC7mglBEGS148, pUC7mglBEGS155, and pUC7mglBEGS155R. To create the templates for M1 EGSs, the hybridized EGS oligos were inserted into a pUC19-based vector containing the T7 promoter and an M1, pUC7/M1AEFRNAHHITT7, pre-digested with PstI and BstEII, generating the plasmids pUC7M1mlgBEGS52, pUC7M1mlgBEGS148, pUC7M1mlgBEGS155, pUC7M1mlgBEGS155R. These constructs were sequenced and the plasmids digested with BstEII, ethanol-precipitated and dissolved in distilled water, and used as templates for in vitro transcription.

EGS activity assays in vitro

EGS activity assays were performed according to a previous report [17]. The EGS in 100-, 50- or 10-fold molar excess was incubated with 10 nM of 5′ end-labeled or internally labeled target mRNAs in PA buffer (50 mM Tris-C1, pH 7.5, 10 mM MgCl₂, 100 mM NH₄Cl) for 5 min at room temperature. Subsequently, 10 nM of M1 RNA and 100 nM of C5 protein were added to the mixture and further incubated for 30 min at 37°C. For reactions with M1 or M1 EGS RNA alone, 100 nM of M1 or M1 EGS RNA was used in PA100 buffer (PA buffer containing 100 mM MgCl₂). Reactions in 10 μl volume were performed at 37°C for 30 min, and terminated by adding 10 μl of 10 M urea/10% phenol solution. The product was separated on 5% polyacrylamide that contained 7 M urea gels.

Construction of plasmids for the EGS activity assay in E. coli

The plasmids contain the platform expressing both a target mRNA and a specific EGS by using the mglB promoter for the target mglB mRNA and the T7 promoter for various EGSs. An additional ‘C’ was introduced into the -35 region of lacZ on the plasmids in order to inactivate transcription from the lacZ promoter by making a slil site [15].

The full-length mglB gene was amplified by PCR using primers mglBf (5′-GGTACATCAAAAGAGCTTGATGAAATGGA-3′) and mglBr (5′-CACAGGTTGACCGATGAAATCTAGCAAG-3′), containing restriction sites for BamHI and BstEII, respectively. The PCR products was digested with BamHI and BstEII, purified from agarose gel using Ultrafree-MC columns, and cloned into a pUC19-based plasmid vector, pKB2835‘HHC5EGS13’HMH1T, digested with the same restriction enzymes, generating the plasmid pKB2835-mglB.

To make the mutagenesis in the -35 region of lacZ in the plasmids, the HindIII-JHIII fragment, which carries the mutated lacZ promoter, from the plasmid pMlac was cut and inserted into the plasmid pKB2835-mglB to create pMlac-mglB. The HindIII-JHIII fragment was also inserted into the plasmid pKB2835‘HHC5EGS13’HMH1T to create pKB2835-Mlac.

The HindIII- EcoRI fragments from the plasmids pUC7mglBEGS53, pUC7mglBEGS148, pUC7mglBEGS155, pUC7M1mlgBEGS148, and pUC7M1mlgBEGS155 were blunt-ended with the Klenow fragment and inserted into the pMlac-mglB plasmid which was cut with EcoRI, and then blunt-ended with the Klenow fragment. The resultant plasmids were named pMlac-mglB-EGS53, pMlac-mglB- EGS148, pMlac-mglB-EGS155, pMlac-mglB-M1EGS73, and pMlac-mglB-M1EGS148, and pMlac-mglB-M1EGS155.

Northern analysis

Freshly transformed cells were used for Northern analysis. BL21 (DE3) competent cells (150 μl) were mixed with 0.1 μg of the appropriate plasmid and transformed at 42°C, for 90 sec. The transformed cells were cultured overnight at 37°C on an LB plate with ampicillin. It is essential to use freshly transformed cells: when the cells were cultured from the glycerol stock of transformed cells, the expression of EGS was poor very often. A colony was picked from the LB plate and was cultured overnight in LB media containing carbenicillin at 37°C.

The overnight culture was diluted 1:100 and incubated at 37°C to OD600 = 0.6. The cells were split into two tubes and 2 mM (final concentration) IPTG was added into one of the tubes. The cells were further incubated for one hour and total RNA was prepared as described previously [20]. The RNAs (4 μg) were separated on a 2% agarose gel.

Northern blot analysis was performed as described previously [7]. Oligonucleotides of RNA155 (5′-CTTTGTAATGTTTGAGGAGATCATCAAACTACCCAGCAG-3′), 73 compl, 148 compl, 155 compl, and 5S1 (5′-TAC CAT CGG CGG TAC TGA AAT ATC T-3′) were labeled at their 5′ ends using [γ-<sup>32</sup>P]ATP and then used as probes for mglB mRNA, EGS73, EGS148, EGS155, and 5S rRNA, respectively.

Acknowledgments

We thank the members of our laboratory for helpful discussions and advice.

Author Contributions

Conceived and designed the experiments: GX EWL SA. Performed the experiments: GX EWL. Analyzed the data: GX EWL SA. Contributed reagents/materials/analysis tools: MI. Wrote the paper: GX EWL SA.
References

1. Tärnvik A (1989) Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11: 440–451.
2. de Bruin OM, Ladh JS, Nano FE. (2007) The Francisella pathogenicity island protein IgA localizes to the bacterial cytoplasm and is needed for intracellular growth. BMC Microbiol 7: 1.
3. Baron GS, Nano FE (1998) MglA and MglB are required for the intramacrophage growth of Francisella novicida. Mol Microbiol 29: 247–259.
4. Charity JC, Costante-Hamm MM, Balon EL, Boyd DH, Rubin EJ, et al. (2007) Twin RNA polymerase-associated proteins control virulence gene expression in Francisella tularensis. PLoS Pathog 3: e84.
5. Gray CG, Cowley SC, Cheung KK, Nano FE. (2002) The identification of five genetic loci of Francisella novicida associated with intracellular growth. FEMS Microbiol Lett 215: 53–56.
6. Lauriano CM, Barker JR, Yoon SS, Nano FE, Arulanandam BP, et al. (2004) MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc Natl Acad Sci USA 101: 4246–4249.
7. Guerrier-Takada C, Li Y, Altman S (1995) Artificial regulation of gene expression in Escherichia coli by RNase P. Proc Natl Acad Sci USA 92: 11115–11119.
8. Guerrier-Takada C, Salavati R, Altman S (1997) Phenotypic conversion of drug-resistant bacteria to drug sensitivity. Proc Natl Acad Sci USA 94: 8468–8472.
9. McKinney JS, Guerrier-Takada C, Wesolowski D, Altman S (2001) Inhibition of Escherichia coli viability by external guide sequences complementary to two essential genes. Proc Natl Acad Sci USA 98: 6605–6610.
10. McKinney JS, Zhang H, Kuhori T, Galán JE, Altman S (2004) Disruption of type III secretion in Salmonella enterica serovar Typhimurium by external guide sequences. Nucleic Acids Res 32: 848–854.
11. Soler Bistue AJ, Ha H, Sarno R, Don M, Zorreguieta A, et al. (2007) External guide sequences targeting the aac(6’)-Ib mRNA induce inhibition of amikacin resistance. Antimicrob Agents Chemother 51: 1918–1922.
12. Altman S (1993) RNA enzyme-directed gene therapy. Proc Natl Acad Sci USA 90: 10898–108990.
13. Forster AG, Altman S (1990) External guide sequences for an RNA enzyme. Science 249: 783–786.
14. Hansen A, Piräffer T, Zuleeg T, Limmer S, Ciesiolka J, et al. (2001) Exploring the minimal substrate requirements for trans-cleavage by RNase P holoenzymes from Escherichia coli and Bacillus subtilis. Mol Microbiol 41: 131–143.
15. Ko JH, Izadjoo M, Altman S (2000) Inhibition of expression of virulence genes of Yersinia pestis in Escherichia coli by external guide sequences and RNase P. RNA 14: 1656–1662.
16. Kim K, Liu F (2007) Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences. Biochim Biophys Acta 1769: 693–12.
17. Lundblad EW, Xiao G, Ko JH, Altman S (2008) Rapid selection of accessible and cleavable sites in RNA by E. coli RNase P and random external guide sequences. Proc Natl Acad Sci USA 105: 2354–2357.
18. Guerrier-Takada C, Altman S (2000) Inactivation of gene expression using ribonuclease P and external guide sequences. Methods Enzymol 313: 442–456.
19. Ko JH, Altman S (2007) OLE RNA, an RNA motif that is highly conserved in several extremophilic bacteria, is a substrate for and can be regulated by RNase P RNA. Proc Natl Acad Sci USA 104: 7815–7820.
20. Racer MF, Arnez JG, Guerrier-Takada C, Vioque A, Altman S (1990) Preparation and characterization of RNase P from Escherichia coli. Methods Enzymol 181: 361–362.
21. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406–3415.
22. Krupp G, Cherayil B, Frendewey D, Nishikawa S, Soll D (1986) Two RNA species co-purify with RNase P from the fission yeast Schizosaccharomyces pombe. EMBO J 5: 1697–1703.